AnaptysBio Valuation
| ANAB Stock | USD 38.48 0.95 2.53% |
At this time, the firm appears to be overvalued. AnaptysBio shows a prevailing Real Value of $35.85 per share. The current price of the firm is $38.48. Our model approximates the value of AnaptysBio from analyzing the firm fundamentals such as operating margin of (3.68) %, and Return On Equity of -2.15 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting AnaptysBio's valuation include:
Price Book 117.7239 | Enterprise Value 829.1 M | Enterprise Value Ebitda (1.30) | Price Sales 38.135 | Enterprise Value Revenue 27.2089 |
Overvalued
Today
Please note that AnaptysBio's price fluctuation is very steady at this time. Calculation of the real value of AnaptysBio is based on 3 months time horizon. Increasing AnaptysBio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since AnaptysBio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of AnaptysBio Stock. However, AnaptysBio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 38.48 | Real 35.85 | Target 29.75 | Hype 39.43 | Naive 36.18 |
The real value of AnaptysBio Stock, also known as its intrinsic value, is the underlying worth of AnaptysBio Company, which is reflected in its stock price. It is based on AnaptysBio's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of AnaptysBio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of AnaptysBio helps investors to forecast how AnaptysBio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of AnaptysBio more accurately as focusing exclusively on AnaptysBio's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use AnaptysBio's intrinsic value based on its ongoing forecasts of AnaptysBio's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against AnaptysBio's closest peers. If more than one evaluation category is relevant for AnaptysBio we suggest using both methods to arrive at a better estimate.
AnaptysBio Cash |
|
AnaptysBio Valuation Trend
Comparing AnaptysBio's enterprise value against its market capitalization is a good way to estimate the value of AnaptysBio uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
AnaptysBio Valuation Data Drivers
AnaptysBio Total Value Analysis
AnaptysBio is presently forecasted to have valuation of 829.14 M with market capitalization of 1.16 B, debt of 17.81 M, and cash on hands of 442.15 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the AnaptysBio fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
829.14 M | 1.16 B | 17.81 M | 442.15 M |
AnaptysBio Investor Information
About 98.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 6.35. AnaptysBio had not issued any dividends in recent years. Based on the analysis of AnaptysBio's profitability, liquidity, and operating efficiency, AnaptysBio may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.AnaptysBio Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. AnaptysBio has an asset utilization ratio of 3.79 percent. This suggests that the Company is making $0.0379 for each dollar of assets. An increasing asset utilization means that AnaptysBio is more efficient with each dollar of assets it utilizes for everyday operations.AnaptysBio Ownership Allocation
The majority of AnaptysBio outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in AnaptysBio to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in AnaptysBio. Please pay attention to any change in the institutional holdings of AnaptysBio as this could imply that something significant has changed or is about to change at the company.AnaptysBio Profitability Analysis
The company reported the previous year's revenue of 17.16 M. Net Loss for the year was (163.62 M) with loss before overhead, payroll, taxes, and interest of (78.51 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates AnaptysBio's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in AnaptysBio and how it compares across the competition.
About AnaptysBio Valuation
The stock valuation mechanism determines AnaptysBio's current worth on a weekly basis. Our valuation model uses a comparative analysis of AnaptysBio. We calculate exposure to AnaptysBio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of AnaptysBio's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 14.8 M | 15.5 M | |
| Pretax Profit Margin | (9.54) | (10.01) | |
| Operating Profit Margin | (9.58) | (10.06) | |
| Net Loss | (9.54) | (10.01) | |
| Gross Profit Margin | 0.86 | 0.90 |
AnaptysBio Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 26.9 M |
AnaptysBio Current Valuation Indicators
Valuation refers to the process of determining the present value of AnaptysBio and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value AnaptysBio we look at many different elements of the entity such as AnaptysBio's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. AnaptysBio's valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final AnaptysBio's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as AnaptysBio, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use AnaptysBio's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes AnaptysBio's worth.Complementary Tools for AnaptysBio Stock analysis
When running AnaptysBio's price analysis, check to measure AnaptysBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AnaptysBio is operating at the current time. Most of AnaptysBio's value examination focuses on studying past and present price action to predict the probability of AnaptysBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AnaptysBio's price. Additionally, you may evaluate how the addition of AnaptysBio to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |